Lipocine
LPCN
47 hedge funds and large institutions have $24.9M invested in Lipocine in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 2 closing their positions.
1,100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 2
90% more capital invested
Capital invested by funds: $13.1M → $24.9M (+$11.8M)
81% more funds holding
Funds holding: 26 → 47 (+21)
13.36% more ownership
Funds ownership: 29.36% → 42.72% (+13%)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.69M |
| 2 |
EP
Eversept Partners
New York
|
+$2.57M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$1.93M |
| 4 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.74M |
| 5 |
SC
Stempoint Capital
New York
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$1.84M |
| 2 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
-$697K |
| 3 |
PAP
Persistent Asset Partners
Hong Kong
|
-$498K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$40.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$18.4K |
LPCN Hedge Fund Activity: Q1 2026 in Review
47 of the 8,197 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2026, worth a combined $24.9M — up 90% from $13.1M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LPCN positions and 2 closed out — a net gain of 22 holders — while 9 added to existing stakes and 10 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $2.69M. The largest seller was Diadema Partners, cutting an estimated $1.84M.
- 47 institutional investors held Lipocine (LPCN) as of Q1 2026, up from 26 in Q4 2025.
- Funds reported $24.9M of Lipocine stock for Q1 2026, up 90% quarter-over-quarter.
- 24 funds opened new Lipocine positions in Q1 2026 and 2 closed out, a net change of +22 holders.
- The largest Lipocine buyer in Q1 2026 was Ikarian Capital, an estimated $2.69M added.
- The largest Lipocine seller in Q1 2026 was Diadema Partners, an estimated $1.84M sold.
Based on aggregated 13F filings for Q1 2026.